|
1
|
Saleh EM, El-Awady RA and Anis N:
Predictive markers for the response to 5-fluorouracil therapy in
cancer cells: Constant-field gel electrophoresis as a tool for
prediction of response to 5-fluorouracil-based chemotherapy. Oncol
Lett. 5:321–327. 2013.PubMed/NCBI
|
|
2
|
Lewis IJ, Nooij MA, Whelan J, Sydes MR,
Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van
Glabbeke M, et al: Improvement in histologic response but not
survival in osteosarcoma patients treated with intensified
chemotherapy: A randomized phase III trial of the European
osteosarcoma intergroup. J Natl Cancer Inst. 99:112–128. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mintz MB, Sowers R, Brown KM, Hilmer SC,
Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, et
al: An expression signature classifies chemotherapy-resistant
pediatric osteosarcoma. Cancer Res. 65:1748–1754. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scotlandi K, Serra M, Nicoletti G, Vaccari
M, Manara MC, Nini G, Landuzzi L, Colacci A, Bacci G, Bertoni F, et
al: Multidrug resistance and malignancy in human osteosarcoma.
Cancer Res. 56:2434–2439. 1996.PubMed/NCBI
|
|
5
|
Adhikari AS, Agarwal N, Wood BM, Porretta
C, Ruiz B, Pochampally RR and Iwakuma T: CD117 and Stro-1 identify
osteosarcoma tumor-initiating cells associated with metastasis and
drug resistance. Cancer Res. 70:4602–4612. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou J, Wei YH, Liao MY, Xiong Y, Li JL
and Cai HB: Identification of cisplatin-resistance associated genes
through proteomic analysis of human ovarian cancer cells and a
cisplatin-resistant subline. Asian Pac J Cancer Prev. 13:6435–6439.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang X, Yashiro M, Qiu H, Nishii T,
Matsuzaki T and Hirakawa K: Establishment and characterization of
multidrug-resistant gastric cancer cell lines. Anticancer Res.
30:915–921. 2010.PubMed/NCBI
|
|
8
|
Görg A, Drews O, Lück C, Weikand F and
Weiss W: 2-DE with IPGs. Electrophoresis. 30(Suppl 1): S122–S132.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dannenberg JH, David G, Zhong S, van der
Torre J, Wong WH and Depinho RA: mSin3A corepressor regulates
diverse transcriptional networks governing normal and neoplastic
growth and survival. Genes Dev. 19:1581–1595. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen Y, Yang Y, Yuan Z, Wang C and Shi Y:
Predicting chemosensitivity in osteosarcoma prior to chemotherapy:
An investigational study of biomarkers with immunohistochemistry.
Oncol Lett. 3:1011–1016. 2012.PubMed/NCBI
|
|
11
|
Goorin AM, Schwartzentruber DJ, Devidas M,
Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE and Link MP:
Pediatric Oncology Group: Presurgical chemotherapy compared with
immediate surgery and adjuvant chemotherapy for nonmetastatic
osteosarcoma: Pediatric oncology group study POG-8651. J Clin
Oncol. 21:1574–1580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jaffe AB and Hall A: Rho GTPases:
Biochemistry and biology. Annu Rev Cell Dev Biol. 21:247–269. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wheeler AP and Ridley AJ: Why three Rho
proteins? RhoA, RhoB, RhoC and cell motility. Exp Cell Res.
301:43–49. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aznar S and Lacal JC: Rho signals to cell
growth and apoptosis. Cancer Lett. 165:1–10. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Adamson P, Paterson HF and Hall A:
Intracellular localization of the P21rho proteins. J Cell Biol.
119:617–627. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Simpson KJ, Dugan AS and Mercurio AM:
Functional analysis of the contribution of RhoA and RhoC GTPases to
invasive breast carcinoma. Cancer Res. 64:8694–8701. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vega FM, Fruhwirth G, Ng T and Ridley AJ:
RhoA and RhoC have distinct roles in migration and invasion by
acting through different targets. J Cell Biol. 193:655–665. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cho HJ, Baek KE, Park SM, Kim IK, Nam IK,
Choi YL, Park SH, Im MJ, Choi J, Ryu J, et al: RhoGDI2 confers
gastric cancer cells resistance against cisplatin-induced apoptosis
by upregulation of Bcl-2 expression. Cancer Lett. 311:48–56. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Costello PS, Cleverley SC, Galandrini R,
Henning SW and Cantrell DA: The GTPase rho controls a p53-dependent
survival checkpoint during thymopoiesis. J Exp Med. 192:77–85.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lotze MT and Tracey KJ: High-mobility
group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal.
Nat Rev Immunol. 5:331–342. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang W, Jiang H, Zhu H, Zhang H, Gong J,
Zhang L and Ding Q: Overexpression of high mobility group box 1 and
2 is associated with the progression and angiogenesis of human
bladder carcinoma. Oncol Lett. 5:884–888. 2013.PubMed/NCBI
|
|
22
|
Cunha C, Carvalho A, Esposito A, Bistoni F
and Romani L: DAMP signaling in fungal infections and diseases.
Front Immunol. 3:2862012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
White E and DiPaola RS: The double-edged
sword of autophagy modulation in cancer. Clin Cancer Res.
15:5308–5316. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livesey KM, Tang D, Zeh HJ and Lotze MT:
Autophagy inhibition in combination cancer treatment. Curr Opin
Investig Drugs. 10:1269–1279. 2009.PubMed/NCBI
|
|
25
|
Xie M, Kang R, Yu Y, Zhu S, He YL, Xu WQ,
Tang DL and Cao LZ: Enhancive effect of HMGB1 gene silence on
adriamycin-induced apoptosis in K562/A02 drug resistance leukemia
cells. Zhonghua Xue Ye Xue Za Zhi. 29:549–552. 2008.(In Chinese).
PubMed/NCBI
|
|
26
|
Yu Y, Xie M, He YL, Xu WQ, Zhu S and Cao
LZ: Role of high mobility group box 1 in adriamycin-induced
apoptosis in leukemia K562 cells. Ai Zheng. 27:929–933. 2008.(In
Chinese). PubMed/NCBI
|
|
27
|
Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R,
Vernon P, Cao L and Tang D: HMGB1 promotes drug resistance in
osteosarcoma. Cancer Res. 72:230–238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang J, Liu K, Yu Y, Xie M, Kang R,
Vernon P, Cao L, Tang D and Ni J: Targeting HMGB1-mediated
autophagy as a novel therapeutic strategy for osteosarcoma.
Autophagy. 8:275–277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dell'Orco RT, McClung JK, Jupe ER and Liu
XT: Prohibitin and the senescent phenotype. Exp Gerontol.
31:245–252. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Coates PJ, Nenutil R, McGregor A, Picksley
SM, Crouch DH, Hall PA and Wright EG: Mammalian prohibitin proteins
respond to mitochondrial stress and decrease during cellular
senescence. Exp Cell Res. 265:262–273. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Czarnecka AM, Campanella C, Zummo G and
Cappello F: Mitochondrial chaperones in cancer: From molecular
biology to clinical diagnostics. Cancer Biol Ther. 5:714–720. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rizwani W, Alexandrow M and Chellappan S:
Prohibitin physically interacts with MCM proteins and inhibits
mammalian DNA replication. Cell Cycle. 8:1621–1629. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou TB and Qin YH: Signaling pathways of
prohibitin and its role in diseases. J Recept Signal Transduct Res.
33:28–36. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gogvadze V, Orrenius S and Zhivotovsky B:
Mitochondria as targets for cancer chemotherapy. Semin Cancer Biol.
19:57–66. 2009. View Article : Google Scholar : PubMed/NCBI
|
